Live Analyst Rating Changes 1526 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Florent Cespedes
BERN
Florent Cespedes
Bernstein
Wall Street Analyst
★★☆☆☆
#2134
on 13Foresight · ranked by our own returns
38%
Success Rate
-13.4%
Average Return
3 of 8 calls profitable · -27.1% vs benchmark
📈 Across the calls we could measure, roughly 38% of Florent Cespedes's ratings turned a profit when each position was held for 1 year — averaging -13.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

26 Buy 15 Hold 0 Sell
Florent's Stock Coverage 18 ratings · 2026-06-21
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
FR:SAN
Sanofi
 Dec 05, 2025 BUY Strong Buy
+33.0% avg upside
30 analysts
$119.00
60.54% Upside
 ·
DE:BAYN
Bayer
 Nov 24, 2025 HOLD Strong Buy
+33.4% avg upside
28 analysts
$30.00
20.70% Downside
 ·
CH:NOVN
Novartis AG
 Nov 20, 2025 BUY Buy
-9.7% avg upside
30 analysts
$108.00
8.63% Downside
 ·
DE:MRK
Merck KGaA
 Nov 17, 2025 HOLD Buy
+2.0% avg upside
32 analysts
$135.00
1.64% Upside
 ·
GB:0QIU
Novo Nordisk
 Nov 04, 2025 BUY Hold
+40.1% avg upside
28 analysts
$540.00
84.07% Upside
 ·
FR:IPN
Ipsen
 Sep 23, 2025 BUY Hold
-21.8% avg upside
17 analysts
$148.00
5.41% Downside
 ·
NVO
Novo Nordisk
 Sep 09, 2025 BUY Buy
+168.5% avg upside
26 analysts
 — -16.9%
GB:GSK
GlaxoSmithKline
 Aug 01, 2025 BUY Hold
-2.8% avg upside
25 analysts
$2290.00
18.91% Upside
 ·
GB:AZN
AstraZeneca
 Aug 01, 2025 BUY Strong Buy
+12.2% avg upside
26 analysts
$18000.00
36.00% Upside
 ·
CH:ROP
Roche Holding AG
 Aug 01, 2025 BUY Buy
+3.2% avg upside
23 analysts
$345.00
7.92% Upside
 ·
GMAB
Genmab
 Dec 20, 2024 HOLD Buy
+38.3% avg upside
26 analysts
 — +59.4%
GB:0NZT
UCB SA
 Mar 26, 2024 HOLD Buy
-13.3% avg upside
19 analysts
$127.00
49.06% Downside
 ·
LLY
Eli Lilly & Co
 Feb 15, 2023 SELL Strong Buy
-10.5% avg upside
47 analysts
$278.00
74.74% Downside
 -128.1%
JNJ
Johnson & Johnson
 Apr 21, 2022 HOLD Strong Buy
-3.5% avg upside
36 analysts
$187.00
18.06% Downside
 -8.9%
NVS
Novartis
 Mar 23, 2021 BUY Hold
-7.7% avg upside
24 analysts
$132.58
9.77% Downside
 +3.3%
PFE
Pfizer
 Nov 01, 2018 HOLD Buy
+34.2% avg upside
45 analysts
$43.00
70.48% Upside
 -9.0%
SNY
Sanofi
 Apr 15, 2015 BUY Strong Buy
+74.5% avg upside
20 analysts
 — -13.3%
TEVA
Teva Pharmaceutical
 Dec 13, 2012 BUY Buy
-6.6% avg upside
39 analysts
$48.00
52.56% Upside
 +5.9%
🔒 13 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Florent Cespedes — Frequently Asked Questions
How accurate are Florent Cespedes's stock ratings?
Based on the calls 13Foresight could measure, about 38% of Florent's ratings were profitable over a one-year hold, with an average return of -13.4% per rating, or -27.1% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Florent ranked on 13Foresight?
Florent Cespedes is currently ranked #2134 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Florent cover?
Florent most recently has ratings on FR:SAN, DE:BAYN, CH:NOVN, DE:MRK, GB:0QIU, FR:IPN, NVO, GB:GSK, GB:AZN, CH:ROP, GMAB, GB:0NZT and 6 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.